PD-L1 ImmunoPET on the basis of Avidin/Biotin pre-targeted cancer imaging
Biochemical and Biophysical Research Communications · 2023
DOI: 10.1016/j.bbrc.2023.06.059 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2023. Verfasst von Zhongqiu Guo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Shanghai Changhai Hospital, Shanghai, 200433, China. Hauptthemen laut MEDLINE: Biotin, Colonic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Shanghai Municipal Health Commission.
Abstract (Originalsprache)
This study aimed to establish the radio-immune imaging protocol on the basis of Avidin/Biotin system. The programmed death-ligand 1 (PD-L1) antibody (Atezolizumab) was employed as the primary molecule in targeting PD-L1, and the two-step strategy, consisting of the first injection of Avidin-conjugated PD-L1 monoclonal antibody (Atezolizumab) and the second injection of 7.4 MBq 68Ga-Biotin with a 60 h interval, was then verified on the colon cancer-bearing mice. PET imaging was performed at 30, 90, 180 min to measure the standard uptake value and tumor to liver ratios. Cellular binding experiments and in vivo distribution showed that the conjugation of Avidin did not affect the affinity of Atezolizumab to PD-L1 antigen. Biotin was radio-labeled with 68Ga with radiolabeling efficiency of 70.5 ± 3.5% and purification was needed to increase the radiochemical purity. For PD-L1-positive tumors, SUVmax was 0.38 ± 0.06 in the Avidin-Atezolizumab pre-treated mice at 90 min; the tumor/liver ratios of pre-targeting group were 1.06 ± 0.19 and 0.97 ± 0.16 at 30 and 90 min, while the absence of pre-treatment of Avidin was of the lower ratios as 0.88 ± 0.01 and 0.54 ± 0.11 when 68Ga-Biotin served as the radiopharmaceutical as well. In conclusion, pre-targeting immunoPET strategy can elevate the target-to-nontarget ratio, decrease the blood background and shorten the interval between injection of radiopharmaceuticals and PET scan, providing a highly PD-L1-specific and sensitive imaging method for the detection of tumorous immune micro-environment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Shanghai Changhai Hospital, Shanghai, 200433, China.
- Department of Radiology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Hubei, 441021, China.
- Department of Radiology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Hubei, 441021, China. Electronic address: ch2xf@163.com.
- Department of Nuclear Medicine, Shanghai Changhai Hospital, Shanghai, 200433, China; Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China. Electronic address: lixiao_nm@smmu.edu.cn.
- Department of Nuclear Medicine, Shanghai Changhai Hospital, Shanghai, 200433, China. Electronic address: changjing.zuo@qq.com.
Förderung
- Shanghai Municipal Health Commission
Zitieren
APA
Guo, Z., Zhu, L., Xu, W., Luo, X., Chen, H., Li, X., & Zuo, C. (2023). PD-L1 ImmunoPET on the basis of Avidin/Biotin pre-targeted cancer imaging. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2023.06.059
Vancouver
Guo Z, Zhu L, Xu W, Luo X, Chen H, Li X, et al. PD-L1 ImmunoPET on the basis of Avidin/Biotin pre-targeted cancer imaging. Biochemical and Biophysical Research Communications. 2023. doi:10.1016/j.bbrc.2023.06.059
BibTeX
@article{Guo2023,
author = {Guo, Zhongqiu and Zhu, Lizhi and Xu, Wen and Luo, Xiu and Chen, Hui and Li, Xiao and Zuo, Changjing},
title = {PD-L1 ImmunoPET on the basis of Avidin/Biotin pre-targeted cancer imaging},
journal = {Biochemical and Biophysical Research Communications},
year = {2023},
doi = {10.1016/j.bbrc.2023.06.059}
}
EUVIMED